Drug Profile
Research programme: Tribody antibody drug conjugates - Biotecnol/PolyTherics
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Biotecnol Inc.; PolyTherics
- Class Antibodies; Drug conjugates
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in USA
- 23 Oct 2012 Early research in Cancer in USA (unspecified route)